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MAX MAUNEY: The Importance of Continuity of Care Among Older Adults on 
Chronic Opioid Therapy 
(Under the Direction of Dr. Yi Yang) 
 
 
Objective: The purpose of this study was to define continuity of care and prescriber 
characteristics among older adults with chronic non-cancer pain who are on long-term 
opioid therapy. Also, it will evaluate the connection between continuity of care and 
prescriber characteristics on the risk of opioid-related adverse events among older adults 
on chronic opioid therapy. The main goal is to observe the relationship between 
continuity and the related adverse events that may arise. 
Methods: This study utilized a nested case-control using a 5% random sample of the 
National Medicare data between 2012 and 2016. This data used a random sample of 
beneficiaries in the United States and included a plethora of information regarding their 
provider visits. The control group was defined as those who entered the study cohort but 
did not experience any related adverse events or death. There were two numerical ways 
to determine COC (COCI and HI). Statistical comparisons through a Chi-Square test and 
Conditional logistic regression models were used to visually compare COC and opioid-
related adverse events.  




Results: The mean COCI score was 0.65 in the 6-month period prior to cohort entry. 
Those with low COC were found to have higher odds of the outcome compared to those 
with higher COC. Those seeing a pain specialist had lower odds of the composite 
outcome. The adjusted results showed similar findings that were expected. 
Conclusion: It was found that there was a positive correlation between continuity of care 
and having less opioid-related adverse events for patients with CNCP. Also, provider 
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Approximately 20% of people worldwide are affected by chronic non-cancer pain 
and around one in five adults in the United States suffer from this pain (Mathieson, et al. 
& Bonezzi et al. 2020). As the prevalence of chronic pain increases with age, CNCP 
commonly affects older adults and is most frequently associated with musculoskeletal 
disorders, such as degenerative spine conditions and arthritis (American Geriatrics 
Society Panel 2009). In addition to a significant impact on functionality and autonomy, 
chronic pain is associated with substantial disability in the elderly population (Reid, 
Eccleston, Pillemer 2015). Opioid analgesics are often used to manage such persistent 
pain even though there is limited evidence to support the long-term use in older adults 
(Chou et al. 2015). As stated by the American Geriatrics Society Panel, “persistent pain 
commonly affects older people and is most frequently associated with musculoskeletal 
disorders, such as degenerative spine conditions and arthritis” (Els et al. 2017).  Long-
term opioid therapy in older adults can lead to increased risks and adverse events like 
cognitive impairment, fall injuries, nausea, constipation, etc. (Baldini, Von Korff, Lin 
2012). As stated by Dunn et al., long-term opioid therapy is more common, especially in 
adults with chronic noncancer pain;” this can lead one to hypothesize a positive 
correlation with long-term opioid therapy and negative effects (Dunn, Saunders, Rutter 
2010). Managing non-cancer chronic pain in older adults, particularly in those with 
several comorbidities and polypharmacy is difficult. Existing research identifies risk 




factors of opioid-related adverse outcomes for patients on long-term opioid therapy. 
These factors include treatment characteristics such as dosage of opioids and type of 
opioids, patient characteristics such as disability status, comorbidities, and use of other 
medications. In addition, the number and types of providers managing long-term opioid 
therapy may be critical. Previous research has indicated that obtaining prescriptions from 
multiple prescribers or pharmacies, termed provider shopping, may be an indicator of 
opioid misuse. In fact, the pharmacy quality alliance has endorsed the number of 
prescribers as a measure indicative of quality of opioid use. The use of multiple 
prescribers also leads to a lack in continuity of care which may lead to poor management 
of opioid therapy and higher risk of adverse outcomes. Similarly, whether a pain 
specialist is involved in the care of the patient may influence the risk of adverse outcomes 
associated with long-term opioid therapy. 
The American Academy of Family Physicians defined continuity of care as “the 
process by which the patient and the physician are cooperatively involved in ongoing 
health care management toward the goal of high quality, cost-effective medical care” 
(Gulliford et al. 2006). Continuity of care can be measured quantitatively. Bice and 
Boxerman proposed a formula to measure the continuity of care (COC) through the 
equation given in figure 1. 
  
     Figure 1: Bice and Boxerman COC Equation (Sudhakar-Krishnan, Vidya, Rudolf 
2007) 




In this equation, n is the total number of visits, nj is the number of visits to a 
provider (j), s is the total number of providers (s above the sigma), and the maximum 
value for continuity is 1” (Bice, Boxerman).  The index represents the extent to which an 
individual patient visits single or group of providers over a specified period (Pollack et al. 
2016). 
Continuity of care is found to be associated with a high degree of patient 
satisfaction, higher rates of medication compliance, decrease adverse events and better 
management of elderly patients with chronic conditions (Dreiher, et al. 2012).It is noted 
that patients using multiple prescribers and multiple pharmacies are more likely to 
experience adverse events due to more variability and room for error.  
Prescribing continuity is fundamental to high-quality care and better care 
experiences. Fragmented care from multiple providers and increment in number of 
providers are associated with a greater risk of adverse events caused by drugs (Beadles, et 
al. 2014). A study by Hallvik et al. found out that lower prescribing continuity in long-
term opioid use, as measure by COCI, was associated with the likelihood of receiving 
risky opioid prescriptions and opioid-related adverse events including overdose-related 
hospitalizations and other adverse events (Hallvik, et al.) Clear comprehension of the 
association between continuity of opioid prescribing and opioid-related adverse events is 
necessary to effectively management of CNCP through chronic opioid therapy. 
Therefore, the overall goal of this paper is to evaluate the importance of appropriate 
patient management while undergoing safe use of long-term opioid prescribed therapy. 
The specific aims are to describe the continuity of care and prescriber characteristics 
among older adults on long-term opioid therapy with CNCP and to also evaluate the 




relationship between COC and prescriber characteristics on the risk of opioid-induced 























Study Design and Data Source 
This study used a nested case-control design using a 5% random sample of the 
National Medicare data between 2012-2016. The data includes demographic 
characteristics from a 5% random sample of all Medicare beneficiaries in the United 
States, and their inpatient, outpatient, and pharmacy claims containing information on 
diagnosis codes, procedure codes, and medication fills, linked using an encrypted 
beneficiary identifier. An institutional review board approved the study and a data use 
agreement for use of Medicare data was obtained from the Centers for Medicare & 
Medicaid Services prior to the study. 
Cohort Definition 
Medicare beneficiaries identified to be on a new chronic opioid therapy episode 
between July 1, 2012 and December 31, 2016 were deemed eligible for cohort entry. 
Based on extant literature, a new chronic opioid therapy episode was defined as presence 
of at least three prescription claims fills for opioids and a cumulative 45 days of opioid 
possession in any 90-day period during the study, with no history of opioid prescription 
fills in the 6-month period prior to start of the chronic opioid therapy episode (Dunn, 
Kate M., et al. 2010 & Ramachandran, S., et al. 2021) The 91st day after initiation of the 
chronic opioid therapy episode was considered as the “cohort entry date” for beneficiaries 
that were at least 65 years of age or older as of the start date of the opioid use episode and 




continuously enrolled in Medicare Parts A, B, and D in the 12-month period prior to 
cohort entry. Additionally, beneficiaries were required to have no history of cancer and at 
least two claims with diagnoses for a chronic non-cancer pain (CNCP) condition within a 
30-day window in the 12-month period prior to the beginning of the chronic opioid use 
episode. Beneficiaries entering the study cohort remained a part of the cohort until the 
first occurrence of one of the following events – outcome of interest, death, cancer 
diagnosis, loss of Medicare eligibility, or end of the study period.  
Case Definition 
Multiple opioid-related adverse events – opioid-induced respiratory depression 
(OIRD), opioid-related overdose (OD), all-cause mortality, and a composite outcome of 
the first occurrence of any of the three stated events, were assessed in this study. Separate 
cases and matching controls were determined for each of the events. Cases were defined 
as beneficiaries from the cohort who had an episode of either OIRD or OD, or died 
before the end of the study period. The date of the first occurrence of an event of interest 
was considered as the “index date”.  
Based on prior literature, an OIRD episode was identified based on presence of a 
diagnosis code for prescription opioid-related poisoning and a procedure code for life-
threatening respiratory or central nervous system depression, or mechanical ventilation or 
critical care within one day of the prescription opioid-related poisoning (Zedler, B., et al. 
2014 and 2018). Consistent with previous literature, OD was determined based on 
presence of a diagnosis code for opioid-related poisoning, or a diagnosis code for opioid-
related adverse event with a diagnosis code for opioid overdose on the same day (Dunn, 




Kate, et al. 2010). For beneficiaries who died during the study period, date of death was 
obtained from the Master Beneficiary Summary File (MBSF).  
Control Definition 
Controls were defined as beneficiaries who entered the study cohort but did not 
experience any opioid-related adverse event or death as of the index date of their matched 
case. Incidence density sampling was employed to select one control for each case, to 
allow for random sampling from the pool of eligible controls, such that the time at risk of 
an opioid-related adverse event or death for each control beneficiary was equal to or more 
than that of their matched case. This technique allows for beneficiaries that were selected 
as controls at the given time at risk to also serve as a case at a future time point. 
Moreover, it is possible for a particular beneficiary to serve as a control for more than 
one case. Cases and controls were matched on age and time of cohort entry.  
Continuity of Care 
Opioid prescribing continuity was determined using the Continuity of Care Index 
(COCI) proposed by Bice and Boxerman, and captures “the extent to which a given 
individual’s total number of visits for an episode of illness or a specific time period are 
with a single or group of referred providers” (Bice, Boxerman 1977). In the context of the 
present study, COCI was calculated based on opioid prescriptions filled and its value 
ranged from 0 (complete fragmentation of care) to 1 (perfect continuity of care). COCI 
scores were classified into quartiles and beneficiaries were assigned to three categories – 
bottom quartile (0-25th percentile), middle quartile (25th–75th percentile), and top quartile 
(more than 75th percentile). 




The Continuity of Care Index was calculated at different time points for the two 
different aims of the study. For aim 1, COCI was calculated in the 6-month period prior 
to the cohort entry date.  For aim 2, COCI was assessed in the 6-month hazard period 
prior to the index date for the case and its matched control.  
Sensitivity analysis was conducted using a different measure of continuity of care 
– the Herfindahl Index (HI). Even though the HI is conceptually similar to that of the 
COCI, in the sense that both measure “the degree of coordination required between 
different providers during an episode” (Pollack, et al. 2016), it is calculated slightly 
differently.   
Control Variables 
Covariates included in the study included beneficiary sociodemographic 
characteristics, clinical characteristics, and opioid medication use characteristics. 
Sociodemographic characteristics included race, sex, Medicare low-income subsidy (LIS) 
status, and region of residence. Clinical characteristics controlled for in the study include 
comorbidity score – assessed using the Deyo adaptation of the Charlson Comorbidity 
Index (CCI) in addition to separate indicators for presence of – multiple CNCP 
conditions, mental illnesses, renal insufficiency, hypnosis, substance abuse disorder, 
hepatic insufficiency, Parkinson’s disease, chronic obstructive pulmonary disorder 
(COPD), sleep apnea or other sleep disorders. Additionally, history of overdose and 
OIRD were assessed (Deyo et al. 1992). Opioid medication uses characteristics included 
average daily dose of opioids prescribed – in morphine milligram equivalent (MME) 
units, and type of opioid prescribed. Based on CDC guidance and prior research, average 
daily dose of opioids was divided into the following categories: less than 20 MME, 20-50 




MME, and 50 MME or above (CDC 2021). Type opioid prescribed were categorized into 
– short-acting, long-acting, and combination products. All covariates were assessed prior 
to the index date.  
Statistical analysis 
Descriptive statistics were used to report beneficiary characteristics, and 
continuity of care. For categorical variables, frequency and percentage distributions were 
reported. Statistical comparisons were conducted between the groups using Chi-Square 
tests. For continuous variables, mean and standard deviation (SD), or median and 
interquartile range were reported, as appropriate. Statistical comparisons for continuous 
variables were conducted using paired t-tests. Conditional logistic regression models 
were used to examine the relationship between continuity of care and opioid-related 
adverse events accounting for the matched case-control data. All analyses were 














Characteristics of the 35,189 Medicare beneficiaries who were new LTOT users are 
shown in Table 1. The mean was 77 years in this group; 24,342 were female (69%), 
29,321 were white (83%), and 15,054 had a low-income status (43%). This sample had 
an average COCI score of 0.65 in the 6-month period prior to cohort entry. 2,165 (9%) of 
beneficiaries received at least one prescription from a pain specialist. 
 
 





































































































Age (SD) 77.19 (8.60) 82.44 (9.30) 82.50 (9.40) 0.07 














































Mental Illness  
 





















33 (54.10) 28 (45.90) 0.513 
 
 
Sleep Apnea  
 






































443 (41.29) 630 (58.71) <0.001* 
 
 
Anticonvulsants   
 
462 (45.65) 550 (54.35) <0.001* 
 
 
Antidepressants   
 
494 (43.26) 648 (56.74) <0.001* 
 
 
NSAIDs   
 





















92 (49.46) 94 (50.54) 0.88 
 
 
Multiple CNCP   
 























*Significant at α=0.05 level, COCI=Continuity of Care Index, HI= Herfindahl Index, ^Beneficiaries who received at 
least one opioid prescription from a pain specialist, SA=Short Acting, LA=Long Acting, MME=Morphine 
Milligram Equivalents, LIS=Low Income Status, COPD=Chronic Obstructive Pulmonary Disease, 
OIRD=Opioid Induced Respiratory Depression, Avg=Average, CNCP=Chronic Non-Cancer Pain, 
NSAIDs= Nonsteroidal Anti-Inflammatory Drugs. 
Outcomes 
1,122 patients experienced the composite outcome. After selection of matched 
cases and controls, the median duration of time between cohort entry and the index date 
for study subjects who experienced the composite outcome was 254.5 days (IQR: 77-
519). The mean COCI for cases was 0.70 (SD of 0.26) and for controls was 0.75 (SD of 
0.30). Similarly, the mean HI for cases was 0.74 (SD of 0.26) and for controls was 0.79 
(SD of 0.25).  
Unadjusted Analysis 
Unadjusted results of the conditional logistic regression models are reported in 
Table 2. It was found that beneficiaries with low COC (OR= 1.61 [95% CI 1.28 - 2.02]) 
had higher odds of the outcome relative to those with a higher COC. Beneficiaries with 
medium COC had 65% (OR= 1.65 [95% CI 1.33 - 2.04]) higher likelihood of 
experiencing the composite outcome relative to high continuity of care. Beneficiaries 
with medium continuity of care had 65% (OR = 1.65 [95% CI 1.33–2.04]) higher 
likelihood of experiencing the composite outcome relative to high continuity of care. 
Additionally, beneficiaries who received at least one opioid prescription from a pain 
specialist had 34% (OR = 0.66 [95% CI 0.48 - 0.93]) lower odds of the composite 




outcome compared to those who did not receive any opioid prescription from a pain 
specialist. 
Table 2. Conditional Logistic Regression Model Results  
using Continuity of Care Index (COCI) (Unadjusted) 
Patient characteristics Composite outcome 
 
 






















                                      *Significant at α=0.05 level, COCI=Continuity of Care Index, Ref=Reference category,  
                                      % Beneficiaries who received at least one opioid prescription from a pain specialist. 
Adjusted Analysis 
Table 3 presents adjusted results of the conditional logistic regression model for 
the composite outcome. After adjusting for all control variables, low continuity of care 
(OR = 1.46 [95% CI 1.09 – 1.96]) and medium continuity of care (OR = 1.38 [95% CI 
1.05 – 1.81]) were found to be significantly associated with the composite outcome, 
respectively compared to high continuity of care. Receiving at least one opioid 
prescription from a pain specialist had 28% (OR = 0.72 [95% CI 0.47 – 1.10]) lower odds 
of composite outcome relative to those who did not receive any opioid prescription from 
a pain specialist. However, this finding was not significant. We also tested an interaction 
between the COCI term and presence of a prescription from a pain specialist, but this 




term was not found to be significant and was subsequently dropped from the model for 
reasons of parsimony. 
Sensitivity analysis using the Herfindahl Index (HI) showed results similar to 
COCI (Tables 4 & 5) demonstrating the robustness of our analyses.  
 
Table 3. Conditional Logistic Regression Model Results using Continuity of Care 
Index (COCI) (Adjusted) 
Patient characteristics Composite outcome 
 
 





























































































































































Yes 1.09 (0.86-1.38) 0.462 
Antidepressants (Ref=No) 
Yes 1.32 (1.03-1.70) 0.030* 
NSAIDs (Ref=No) 










Yes 1.15 (0.83-1.60) 0.387 
Muscle Relaxants (Ref=No) 
Yes 1.04 (0.69-1.57) 0.841 
Multiple CNCP (Ref=No) 
Yes 0.73 (0.48-1.09) 0.127* 
History of OIRD (Ref=No) 
Yes 0.65 (0.20-2.18) 0.50 













*Significant at α=0.05 level, COCI=Continuity of Care Index, Ref=Reference category, SA=Short Acting, 
LA=Long Acting, MME=Morphine Milligram Equivalents, LIS=Low Income Status, CCI=Charlson 
Comorbidity Index, COPD=Chronic Obstructive Pulmonary Disease, OIRD= Opioid Induced Respiratory 
Depression, CNCP=Chronic Non-Cancer Pain, NSAIDs= Nonsteroidal Anti-Inflammatory Drugs. 
  Table 4. Conditional Logistic Regression Model Results  
using Herfindahl Index (HI) (Unadjusted) 
Patient characteristics Composite outcome 
 
 






















                                      *Significant at α=0.05 level, HI=Herfindahl Index, Ref=Reference category,  
                                      % Beneficiaries who received at least one opioid prescription from a pain specialist. 
 
Table 5. Conditional Logistic Regression Model Results for Composite Outcome 
using Herfindahl Index (HI) (Adjusted) 
Patient characteristics Composite outcome 
 
 






















































































































































COPD (Ref=No)   




Yes 1.14 (0.89-1.47) 0.303 
Anticonvulsants (Ref=No) 
Yes 1.09 (0.86-1.38) 0.464 
Antidepressants (Ref=No) 
Yes 1.32 (1.03-1.70) 0.034* 
NSAIDs (Ref=No) 










Yes 1.15 (0.83-1.60) 0.388 
Muscle Relaxants (Ref=No) 
Yes 1.04 (0.69-1.57) 0.852 
Multiple CNCP (Ref=No) 
Yes 0.73 (0.48-1.09) 0.124 
History of OIRD (Ref=No) 
Yes 0.65 (0.19-2.16) 0.476 









*Significant at α=0.05 level, HI= Herfindahl Index, Ref=Reference category, SA=Short Acting, LA=Long 
Acting, MME=Morphine Milligram Equivalents, CCI= Charlson Comorbidity Index, LIS=Low Income 
Status, COPD=Chronic Obstructive Pulmonary Disease, OIRD= Opioid Induced Respiratory Depression, 













Throughout recent years, the word “epidemic” seemed to only apply to viral 
diseases such as COVID-19. The thought of something this severe is seen as something 
obvious, even though the United States has been dealing with a silenced self-created 
epidemic of its own. Addiction is not uncommon nor is it new, but the way it has become 
so centered around medicine has become alarming. In today’s world, there are many 
substances placed on a list considering them “illegal,” and for good reason. However, 
some “legal” substances that are still being prescribed and given out are statistically just 
as dangerous. Opioids are increasingly attracting more victims, and it seems to have no 
end in sight. It is not just about the drug itself, but how it ended up in so many hands of 
American citizens.  
This study observed the safety of opioid use in the long-term. This was obtained 
using a nationally representative cohort of Medicare-eligible older adults with CNCP. 
The evaluation of prescribing characteristics along with the incidence of opioid-related 
adverse events was important to the data. It was found that less than 1 out of 10 adults 
starting a new LTOT episode received at least one prescription from a pain specialist. 
The COC of opioid prescribing was obtained two different ways – through COCI and HI. 
It was also found that participants had a moderate degree of continuity during their initial 
long-term opioid use episode. It was also found that those with greater COC had lower 
odds of experiencing any opioid-related adverse event, but the presence of a prescription 




from a pain specialist did not significantly impact risk of any adverse events. These 
findings present significant evidence to help improve safety of LTOT among older adults 
suffering from CNCP. 
This study was able to find that after accounting for dose and type of opioid 
therapy, some individuals had nearly 50% greater odds of experiencing an adverse event 
as compared to those who had perfect COC. These same individuals were in the lowest 
quartile of continuity of opioid prescribing as well. Hallvik and colleagues’ findings did 
represent unadjusted results from one state, this study confirms the important of COC 
regarding opioid prescribing using two different measurements (Hallvik et al., 2018). 
Previous studies have examined the impact of COC and have found that patients with 
high COC have lower rates of mortality (Gray et al., 2018), preventable hospitalizations 
(Cheng et al., 2010; Nyweide et al., 2013), receive fewer unnecessary medical services 
(Romano et al., 2015), have more emergency room visits (Kern et al., 2019), higher 
healthcare costs and adverse outcomes (Amjad et al., 2016). Most previous research 
examining continuity regarding opioid prescribing gives an approach that quantifies the 
number of prescribers or pharmacies used per individual. Those individuals that use 
multiple prescribers are engaging in a behavior that may be indicative of harmful drug 
use (Cepeda et al., 2012). However, this may not be reflective of non-medical use of 
prescription opioids among older adults as prevalence would be assumed to be lower for 
this age group. Ensuring continuity of opioid prescribing for older adults is a way to 
ensure safety. Measures that can evaluate quantitatively, such as COCI or HI, can be 
more applicable rather than using the number of unique prescribers. This can be 




supported in that continuity of care has been found to be more appropriate for control of 
CNCP (Satterwhite et al., 2019).  
This study found that individuals having at least one opioid prescription from a 
pain specialist were not less likely to experience and opioid-related adverse event. This 
may come as a surprise, but no previous studies have been able to correlate this 
relationship between prescriptions from pain specialists and adverse events. However, a 
significant amount of evidence supports the role that pain specialists play in being 
consulted for treatment of chronic pain (Patwardhan et al., 2018; Hanna et al., 2018). 
Findings from other research show that pain specialists prescribe opioid medications 
more often than primary care providers, but their prescriptions are likely to be for lower 
dosages (Alamanda et al., 2016; Pan, Blankey, & Hughes, 2019). Pain specialists have 
more training, knowledge, and less negative perceptions of LTOT (Hsu et al., 2021; 
McCarberg et al., 2013; Varrassi & Muller-Schwefe, 2012). It is possible that the 
findings in this study are indicative that having at least one prescription from a pain 
specialist does not confer more confidence in specialists being involved in treatment. The 
odds ratio for the pain specialist variable changed from significant to non-significant after 
adjustment of other covariates; this may suggest that a more complex relationship may be 
at play involving the pain specialist. It could be that after accounting for continuity of 
opioid prescribing, provider specialty does not significantly improve safety in LTOT. 
This could be a huge finding; previous studies have shown that pain specialists are not 
easily accessible (Wiznia et al., 2017) and have called for greater numbers of allied 
providers such as pain-specialist pharmacists (Atkinson, Gulum, & Forkum, 2016). 
Regardless, a centered focus on continuous patient management with higher COC, 




regardless of provider specialty, may hold a potential for improving the safety for patients 
on LTOT.  
However, this study’s findings have to be interpreted with context of some 
limitations. First, this study operationalized continuity of opioid prescribing using COCI 
and HI. Both of these measures have limitations within them. Both of these assume that 
repeated visits to the same provider allow for greater continuity, but neither measure is 
able to capture the content for each visit with said provider. Management of chronic 
conditions requires a team of providers that work together in various aspects of care for 
said patient, and this itself cannot be captured by a number generated through COCI or 
HI. Next, this study design estimated COCI and HI during a 6-month duration prior to the 
index date during which individuals were required to have at least 3 prescriptions filled 
for opioid medications. If the number of prescriptions is low, the COCI and HI may yield 
unreliable results. The findings in this study are in line with the hypothesis, but studies 
done over longer durations would need to be able to validate these same results. Also, 
this study does not account for prescriptions paid for using cash per the administrative 
claims data limitation. This study also only utilized information for those enrolled in 
Medicare Advantage plans and also excluded those younger than 65 years of age. Both of 










This study showed that Medicare-enrolled adults over the age of 65 who initiate LTOT 
have moderate levels of COC and only a small portion of them receive prescriptions from 
pain specialists. It was also found that continuity of care, but not provider specialty, was 
significantly associated with fewer opioid-related adverse event among older adults with 
Chronic Non-Cancer Pain.  
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